View Filing Data

Document and Entity Information	6 Months Ended
Jun. 30, 2015
Document and Entity Information
Entity Registrant Name	OptimizeRx Corp
Entity Central Index Key	0001448431
Amendment Flag	true
Amendment Description	On May 4, 2015, we filed with the Securities and Exchange Commission a registration statement on Form S-1 (File No. 333-203820), which was amended by a pre-effective amendment filed on June 1, 2015, to register the offer and sale of 849,139 shares of our common stock, $0.001 par value per share, of which 804,139 shares of common stock are issuable upon the exercise of warrants. The Registration Statement was declared effective by the Commission on June 16, 2015. This Post-Effective Amendment No. 1 to the Form S-1/A is being filed to include a revised audit opinion from our independent auditor, KLJ & Associates, LLP. All securities offered hereby are being offered on a delayed or continuous basis. We are not registering any additional securities under this Post-Effective Amendment. All filing fees payable in connection with the registration of these securities were previously paid by us in connection with the filing of the Form S-1.
Document Type	S-1
Entity Filer Category	Smaller Reporting Company
Document Period End Date	Jun. 30, 2015

Condensed Consolidated Balance Sheet (Unaudited) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Current Assets
Cash and cash equivalents	$ 3,645,878	$ 3,446,973	$ 1,118,243
Accounts receivable	1,918,419	2,100,381	1,511,709
Prepaid expenses	76,376	28,093	11,771
Total Current Assets	5,640,673	5,575,447	2,641,723
Property and equipment, net	10,674	12,813	15,057
Other Assets
Patent rights, net	901,491	930,854	885,950
Web development costs, net	424,075	504,643	404,986
Security deposit	5,049	5,049	5,049
Total Other Assets	1,330,615	1,440,546	1,295,985
TOTAL ASSETS	6,981,962	7,028,806	3,952,765
Current Liabilities
Accounts payable - trade	172,183	200,372	188,739
Accounts payable - related party	570,000	570,000	570,000
Accrued expenses	9,851	25,459	12,000
Revenue share payable	1,190,995	1,502,761	1,287,552
Deferred revenue	336,213	120,130	226,272
Total Liabilities	2,279,242	2,418,722	2,284,563
Stockholders' Equity
Common stock value	22,950	22,867	14,817
Preferred stock value
Stock warrants	2,153,295	2,153,295	18,148,049
Additional paid-in-capital	27,806,253	27,595,609	8,875,155
Stock Payable	1,132,148	963,063	0
Deferred stock compensation	(18,750)		(270,462)
Accumulated deficit	(26,393,176)	(26,124,750)	(25,099,357)
Total Stockholders' Equity	4,702,720	4,610,084	1,668,202
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 6,981,962	$ 7,028,806	$ 3,952,765

Condensed Consolidated Balance Sheet (Parenthetical) (Unaudited) - $ / shares	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Common stock par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000	500,000,000
Common stock, shares issued	22,949,819	22,867,319	14,817,496
Common stock, shares outstanding	22,949,819	22,867,319	14,817,496
Preferred Stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred stock, shares issued			65
Preferred stock, shares outstanding			65

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
NET REVENUE	$ 1,705,457	$ 1,426,808	$ 3,193,010	$ 2,716,236	$ 6,502,962	$ 4,679,741
REVENUE SHARE EXPENSE	882,327	730,140	1,638,768	1,291,551	3,221,534	1,861,316
GROSS MARGIN	823,130	696,668	1,554,242	1,424,685	3,281,428	2,818,425
Operating expenses
Stock-based compensation					1,172,242	523,382
Depreciation and amortization			159,337	115,828	264,340	193,791
Lawsuit settlement					400,000
Other operating expenses					2,471,174	2,368,788
Total Operating expenses	980,659	896,529	1,823,269	2,386,747	4,307,756	3,085,961
INCOME (LOSS) FROM OPERATIONS	(157,529)	(199,861)	(269,027)	(962,062)	(1,026,328)	(267,536)
OTHER INCOME (EXPENSE)
Interest income	304	223	601	329	935	246
Interest expense					0	0
TOTAL OTHER INCOME	304	223	601	329	935	246
INCOME LOSS BEFORE PROVISION FOR INCOME TAXES	(157,225)	(199,638)	(268,426)	(961,733)	(1,025,393)	(267,290)
PROVISION FOR INCOME TAXES					0	0
NET INCOME (LOSS)	$ (157,225)	$ (199,638)	$ (268,426)	$ (961,733)	$ (1,025,393)	$ (267,290)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC	22,924,819	23,241,707	22,917,678	20,355,651	22,382,415	14,388,017
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: FULLY DILUTED					24,008,353	21,196,096
NET INCOME (LOSS) PER SHARE: BASIC AND DILUTED (no separate per share amount shown because loss is antidilutive)					$ (0.04)	$ (0.02)
NET INCOME (LOSS) PER SHARE
BASIC	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.05)
DILUTED

Condensed Consolidated Statement of Stockholders' Equity - USD ($)	Total	Preferred Stock Shares [Member]	Common Stock Shares [Member]	Stock Warrant [Member]	Additional Paid-in Capital [Member]	Stock Payable [Member]	Deferred Stock Compensation [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2012	$ 1,404,882	$ 0	$ 14,232	$ 20,058,051	$ 6,164,666	$ 0	$ 0	$ (24,832,067)
Beginning balance, shares at Dec. 31, 2012		65	14,232,496
Issuance of stock options: to employees	7,720				7,720
Issuance of stock options: to consultants	87,278				146,412		(59,134)
Issuance of common stock: for services	105,420		$ 84		141,856		(36,520)
Issuance of common stock: for services, shares			84,000
Issuance of common stock: for severance	0		$ 500		504,500		(505,000)
Issuance of common stock: for severance, shares			500,000
Issuance of common stock: for correction of prior issue	0		$ 1		(1)
Issuance of common stock: for correction of prior issue, shares			1,000
Reclassification for expired warrants	0			(1,910,002)	1,910,002
Expense consulting services	330,192						330,192
Net loss for the year	(267,290)							(267,290)
Ending balance at Dec. 31, 2013	1,668,202	$ 0	$ 14,817	18,148,049	8,875,155	0	(270,462)	(25,099,357)
Ending balance, shares at Dec. 31, 2013		65	14,817,496
Issuance of stock options: to employees	272,804				272,804
Issuance of stock options: to consultants	0				16,935		(16,935)
Issuance of common stock: for services	41,667		$ 167		26,812	14,688
Issuance of common stock: for services, shares			167,065
Issuance of common stock: for cash	8,795,032		$ 8,333		8,408,699	378,000
Issuance of common stock: for cash shares			8,333,333
Issuance of common stock: for warrant exercise	$ 0		$ 446	(694,133)	693,687
Issuance of common stock: for warrant exercise, shares	0		445,765
Issue warrants for equity raise	$ 0			1,110,211	(1,110,211)
Issue stock rights to officers	570,375					570,375
Reclassify expired and redeemed warrants	0			(16,410,832)	16,410,832
Expense consulting services	287,397						287,397
Redeem shares for cash	(6,000,000)	$ 0	$ (896)		(5,999,104)
Redeem shares for cash, shares		(65)	(896,340)
Net loss for the year	(1,025,393)							(1,025,393)
Ending balance at Dec. 31, 2014	4,610,084	$ 0	$ 22,867	$ 2,153,295	$ 27,595,609	$ 963,063	$ 0	$ (26,124,750)
Ending balance, shares at Dec. 31, 2014		0	22,867,319
Net loss for the year	(268,426)
Ending balance at Jun. 30, 2015	$ 4,702,720

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (268,426)	$ (961,733)	$ (1,025,393)	$ (267,290)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	159,337	115,828	264,340	193,791
Stock and options issued for services	361,062	627,354	272,804	94,998
Loss on disposal of assets			3,295	0
Stock-based compensation	110,039	170,611	899,438	435,612
Changes in:
Accounts receivable	181,962	302,202	(588,672)	(894,911)
Prepaid expenses	(48,283)	(30,198)	(16,322)	56,387
Accounts payable	(28,189)	203,714	11,633	134,046
Revenue share payable	(311,766)	(414,563)	215,210	1,196,975
Accrued expenses	(15,608)	(12,000)	13,459	6,000
Deferred revenue	216,083	19,651	(106,142)	177,020
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	246,172	(149,745)	(56,350)	1,132,628
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment		(1,592)	(6,984)	0
Patent rights	(4,517)	(92,624)	(110,551)	(150,588)
Website site development costs	(42,750)	(119,616)	(292,417)	(148,060)
NET CASH USED IN INVESTING ACTIVITIES	(47,267)	(213,832)	(409,952)	(298,648)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock		10,000,000	8,795,032	0
Equity issuance costs		(1,204,968)
Purchase of common and preferred stock and warrants		(6,000,000)
Redemption of common and preferred stock			(6,000,000)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES		2,795,032	2,795,032	0
NET INCREASE IN CASH AND CASH EQUIVALENTS	198,905	2,431,455	2,328,730	833,980
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	3,446,973	1,118,243	1,118,243	284,263
CASH AND CASH EQUIVALENTS - END OF PERIOD	3,645,878	3,549,698	3,446,973	1,118,243
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest			0	0
Cash paid for income taxes			0	0
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for future services			$ 0	$ 270,462

Nature of Business and Basis of Presentation	6 Months Ended	12 Months Ended
Nature of Business and Basis of Presentation	Jun. 30, 2015	Dec. 31, 2014
Nature of Business and Basis of Presentation [Abstract]
NATURE OF BUSINESS AND BASIS OF PRESENTATION	NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION OptimizeRx Corporation is a technology solution company focused on the health care industry. Its objective is to bring better access to better care by leveraging its proprietary technology to provide on demand savings and support within physicians and patients web based platforms, including Electronic Health Records and Patient Portals. Initially defined as a marketing and advertising company through its consumer website, OptimizeRx.com, the Company has matured as a technology solutions provider through its direct to physician solution, SampleMD. SampleMD allows physicians to automatically display and distribute sample vouchers and/or co-pay coupons electronically within the ePrescription platform to pharmacies on behalf of their patients. The SampleMD solution is integrated into the ePrescribing or Electronic Medical Records applications, but can also sit on a prescriber’s desktop. OptimizeRx solutions provide health care institutions with an alternative option to the traditional hassles and issues associated with storing and managing physical drug samples and pre-printed coupons and it provides better access and affordability to patients to improve affordability, adherence and outcomes. In turn, OptimizeRx provides pharmaceutical manufacturers with both direct to consumer and direct to physician channels for more efficiently communicating and promoting their products and savings. The consolidated financial statements for the three and six month periods ended June 30, 2015 and 2014 have been prepared by us without audit pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, all adjustments necessary to present fairly our financial position, results of operations, and cash flows as of June 30, 2015 and 2014, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. The consolidated balance sheet as of December 31, 2014, has been derived from the audited consolidated balance sheet as of that date. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as filed with the Securities and Exchange Commission. The results of operations for the three and six month periods ended June 30, 2015, are not necessarily indicative of the results to be expected for the full year. Certain reclassifications have been made in the prior period’s consolidated financial statements to conform to the current period’s presentation.	NOTE 1 – NATURE OF BUSINESS OptimizeRx Corporation, is a technology solutions company targeting the health care industry. Our objective is to bring better access to better care through connecting patients, physicians and pharmaceutical manufacturers through technology. Originally defined as a marketing and advertising company through our consumer website, we have matured into a technology solutions provider as we launched our direct to physician solution, SampleMD. SampleMD allows physicians to search, print and send available sample trial vouchers and/or co-pay coupons on behalf of their patients. The SampleMD solution is integrated into the physician’s ePrescribing or Electronic Medical Records applications, but could also be a stand-alone desktop application. OptimizeRx solutions provide pharmaceutical manufacturers a direct to physician channel for communicating and promoting their products. It provides health care providers a means to provide sampling and coupons without having to physically store samples on site, and it provides better access and affordability to patients. The company was originally formed as Optimizer Systems, LLC in the State of Michigan on January 31, 2006. It incorporated in the State of Michigan on October 22, 2007 and changed its name to OptimizeRx Corporation. On April 14, 2008, RFID, Ltd., a Colorado corporation, consummated a reverse merger by entering into a share exchange agreement with the stockholders of OptimizeRx Corporation, pursuant to which the stockholders of OptimizeRx Corporation exchanged all of the issued and outstanding capital stock of OptimizeRx Corporation for 1,256,958 shares of common stock of RFID, Ltd., representing 100% of the outstanding capital stock of RFID, Ltd. As of April 30, 2008, RFID’s officers and directors resigned their positions and RFID changed its business to OptimizeRx’s business. On April 15, 2008, RFID, Ltd.’s corporate name was changed to OptimizeRx Corporation. On September 4, 2008, a migratory merger was completed, thereby changing the state of incorporation from Colorado to Nevada, resulting in the current corporate structure, in which OptimizeRx Corporation, a Nevada corporation, is the parent corporation, and OptimizeRx Corporation, a Michigan corporation, which is a wholly-owned subsidiary (together, "OptimizeRx" and "the Company").

Stockholders Equity	6 Months Ended	12 Months Ended
Stockholders Equity	Jun. 30, 2015	Dec. 31, 2014
Equity [Abstract]
STOCKHOLDERS EQUITY	NOTE 2 – STOCKHOLDERS EQUITY In January 2015, we issued 12,500 shares of common stock to outside Directors in connection with our Director Compensation plan, which calls for issuance of 6,250 shares per quarter for each Director. Those shares were recorded as stock payable at December 31, 2014. In addition, we recorded an additional 12,500 shares, valued at $16,375 as stock payable at March 31, 2015 for shares to be issued in April 2015 and 12,500 shares, valued at $13,375 were issued in June 2015 for the second quarter payment. In February 2015, we entered into a capital markets advisory agreement covering a one year period, which called for 90,000 shares of common stock to be issued as compensation. These shares were valued at $112,500 and are being amortized to expense over the period of service. 45,000 of these shares were issued in March 2015, with the balance to be issued in August 2015. The agreement was terminated in July 2015, effective in August, and the remaining 45,000 shares will not be issued. The total expense to be recognized will be $56,250 and is being amortized over the period the agreement is in effect. In March 2014, we entered into a securities purchase agreement, pursuant to which we sold 8,333,333 shares of our common stock for $1.20 per share, or gross proceeds of $10,000,000. Placement agents in the offering received commissions equal to approximately 9.7% of gross proceeds, for an aggregate commission of approximately $970,000, including reimbursements for their reasonable out of pocket expenses. Placement agents also received warrants to purchase up to 804,139 shares of our common stock with an exercise price of $1.20 per share and a term of 5 years. The warrants were valued at $1,110,211, have been recorded as equity issuance costs, and were registered on a registration statement that went effective May 28, 2014. In addition to the warrants to placement agents, we also paid cash bonuses of $240,000 to three executive officers, agreed to issue 200,000 shares to three executive officers, and issued 150,000 shares to a consultant, in connection with the equity raise. The stock was valued based on the fair market value on the grant date, which was $630,000 in total. These amounts have been recorded as equity issuance costs, resulting in total equity issuance costs of $2.95 million. The 200,000 shares for the three executive officers have not been issued, but are recorded as stock payable and can be requested by the executive officers at any time. We used the net proceeds of the offering to exercise the securities redemption option agreement, as amended, with Vicis Capital Master Fund that provided us with an option to purchase all of the outstanding shares and derivative securities held by Vicis for total payment of $6,000,000. The shares and derivative securities included the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Common Stock, and warrants to purchase shares of common stock held by Vicis in the Company. The balance of the net proceeds were used for working capital purposes. In January 2014, an executive officer exercised 500,000 stock warrants using the cashless exercise feature included in the warrants. In exchange for the 500,000 warrants, 410,348 shares of common stock were issued. In June 2015, we agreed to grant 197,605 fully vested shares of our common stock to two executive officers as bonuses. These shares have not been issued, but are recorded as stock payable and can be requested by the officers at any time. In February 2014, we agreed to grant 337,500 shares of our common stock, half of which vested immediately and half of which vested in August 2014, to two executive officers as bonuses based on their efforts to recapitalize the company to secure approximately $3 million in working capital while reducing fully diluted shares by approximately 7 million shares. These shares have not been issued, but are recorded as stock payable and can be requested by the officers at any time.	NOTE 9 – COMMON STOCK OptimizeRx Corporation has 500,000,000 shares of $.001 par value common stock authorized as of December 31, 2014. There were 22,867,319 and 14,817,496 common shares issued and outstanding at December 31, 2014 and 2013, respectively. On June 1, 2013, the Company entered into a consulting agreement with North Coast Advisors, Inc. for various services. The Company agreed to issue 20,000 shares of common stock as of the date of the contract. The Company also agreed to issue an additional 20,000 shares every six months in alignment with the agreement renewal up to the two years of the agreement. The first 20,000 shares were valued at the Company’s common stock closing price as of the date of the contract, which was $1.945/share; and the second 20,000 shares were valued at the Company’s common stock closing price of $1.50/share on the date of issuance, and have been expensed. An additional 10,000 shares were issued in 2014 before the agreement was terminated by the Company. The 2014 shares were valued at $1.85, the closing price of the Company’s common stock on the date of issuance. On June 10, 2013, the Company entered into a capital markets advisory agreement with Taglich Brothers, Inc. for various services. The agreement covered a one year period and the Company agreed to issue 44,000 shares of common stock to Taglich over the term of the agreement. The shares were valued at $1.66, the closing price of the stock on the date of the agreement and were written off over the term of the agreement. The shares were issued in June 2014 upon expiration of the contract. On September 20, 2013, the Company entered into a separation agreement that included post-employment consulting services with the former CEO of the Company. The Company agreed to issue 500,000 shares of common stock, 250,000 shares immediately and 250,000 by January 1, 2014. The shares have been issued and the Company recognized the entire issuance in the December 31, 2013 shares outstanding. The shares were valued at $505,000 and $174,808 of that amount remained as deferred stock compensation as of December 31, 2013, but has been fully amortized to expenses as of December 31, 2014. In March 2014, the Company entered into a securities purchase agreement, pursuant to which the Company sold 8,333,333 shares of the Company’s common stock for $1.20 per share, or gross proceeds of $10,000,000. Placement agents in the offering received commissions equal to approximately 9.7% of gross proceeds, for an aggregate commission of approximately $970,000, including reimbursements for their reasonable out of pocket expenses. Placement agents also received warrants to purchase up to 804,139 shares of the Company's common stock with an exercise price of $1.20 per share and a term of 5 years. The warrants were valued at $1,110,211, have been recorded as equity issuance costs, and were registered on a registration statement dated May 28, 2014. In addition to the warrants to placement agents, the Company also paid cash bonuses of $240,000 to three executive officers, agreed to issue 200,000 shares to three executive officers, and issued 150,000 shares to a consultant, in connection with the equity raise. The stock was valued based on the fair market value on the grant date, which was $630,000 in total. These amounts have been recorded as equity issuance costs, resulting in total equity issuance costs of $2.95 million. The 200,000 shares for the three executive officers have not been issued, but are recorded as stock payable and can be requested by the respective officers at any time. The Company used the net proceeds of the offering to exercise the securities redemption option agreement, as amended, with Vicis Capital Master Fund that provided the Company with an option to purchase all of the outstanding shares and derivative securities held by Vicis for total payment of $6,000,000. The shares and derivative securities included the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Common Stock, and warrants to purchase shares of common stock held by Vicis in the Company. The balance of the net proceeds was used for working capital purposes. In January 2014, an executive officer exercised 500,000 stock warrants using the cashless exercise feature included in the warrants. In exchange for the 500,000 warrants, 410,348 shares of common stock were issued. In October 2014, a consultant exercised 50,000 stock warrants using the cashless exercise feature included in the warrants. In exchange for the 50,000 warrants, 35,417 shares of common stock were issued. In February 2014, the Company agreed to grant 337,500 shares of common stock, half of which vested immediately and half of which vested in August 2014, to two executive officers as bonuses based on their efforts to recapitalize the company to secure approximately $3 million in working capital while reducing potential fully diluted shares by approximately 7 million shares. Stock-based compensation related to these bonuses was $570,375 during the year ended December 31, 2014. These shares have not yet been issued and are recorded as stock payable, but can be requested by the officers at any time. In 2014, the Company adopted a Director Compensation plan for outside Directors. In connection with this plan, 19,565 shares were granted with a total value of $23,166. A total of 7,065 shares were issued in 2014 and 12,500 shares were included in stock payable at December 31, 2014 and issued in January 2015.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Commitments and Contingencies

6 Months Ended

12 Months Ended

Jun. 30, 2015

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 4 – COMMITMENTS AND CONTINGENCIES

Litigation

The company is currently involved in the following legal proceedings.

In September 2014, we initiated litigation against Shadron Stastney, the Company’s previous CEO, in the U.S. District Court in the Eastern District of Michigan as a result of a dispute related to his separation agreement. Mr. Stastney alleged damages related to the non-registration of shares that he was granted as part of his separation agreement signed in September 2013. Under the terms of the contract we are not obligated to register the shares and we deny any obligation to do so. We have requested declarative relief from the court and also requested an injunction from the court preventing Mr. Stastney from continuing to pursue his claims. Mr. Stastney has filed a counterclaim requesting damages of $450,000 related to the nonregistration of his shares. The parties are currently in the discovery process.

In March 2015, we initiated litigation against LDM Group, LLC and PDR Network, LLC in the U.S. District Court in the Eastern District of Missouri related to the breach by LDM, and PDR as successor, of the settlement agreement signed February 28, 2014 related to previous litigation with LDM. LDM has failed to live up to its obligations under the settlement agreement including, but not limited to, not allowing us to distribute our eCoupon programs in the LDM network, not allowing us to distribute the LDM patient education programs, and not providing other information required under the settlement agreement. We are seeking enforcement of the settlement agreement and we are seeking damages in an amount at least equal to the amounts paid to date to LDM under the settlement agreement, which approximates $1.0 million, as well as damages for lost income and business value as a result of LDM’s breach of the agreement.

In March 2015, we also initiated litigation against PDR Network, LLC in the U.S. District Court in the District of New Jersey as a result of PDR’s breach of the Master Services Agreement between the parties requiring PDR to exclusively use our eCoupon solution. We assert that PDR’s acquisition of LDM and the use of the LDM network to distribute coupons by PDR violates the agreement between the parties and we are seeking damages in an amount at least equal the amounts paid to date by us to LDM under the settlement agreement, which approximates $1.0 million, as well as damages for lost income and business value as a result of PDR’s actions.

In May 2015, we filed an amended complaint in the Missouri case to consolidate the two cases and withdrew the case against PDR Networks in the U.S. District Court in the District of New Jersey, without prejudice.

In July, 2015, the U.S. District Court for the Eastern District of Missouri dismissed the case, citing lack of Federal jurisdiction in the matter. We are in the process of refiling the consolidated case against PDR Network and LDM group in State court in Missouri.

NOTE 16 – CONTINGENT LIABILITIES

Legal

The company is currently involved in the following legal proceedings.

In September 2014, we initial litigation against Shadron Stastney, the Company’s previous CEO, in the U.S. District Court in the Eastern District of Michigan as a result of a dispute related to his separation agreement. Mr. Stastney alleged damages related to the non-registration of shares that he was granted as part of his separation agreement signed in September 2013. Under the terms of the contract we are not obligated to register the shares and we deny any obligation to do so. We have requested declarative relief from the court and also requested an injunction from the court preventing Mr. Stastney from continuing to pursue his claims. Mr. Stastney has filed a counterclaim requesting damages of $450,000 related to the nonregistration of his shares.

In March 2015, we initiated litigation against LDM Group, LLC and PDR Network, LLC in the United States District Court in the Eastern District of Missouri related to the breach by LDM, and PDR as successor, of the settlement agreement signed February 28, 2014 related to previous litigation with LDM. LDM has failed to live up to its obligations under the settlement agreement including, but not limited to, not allowing the Company to distribute its eCoupon programs in the LDM network, not allowing the Company to distribute the LDM patient education programs, and not providing other information required under the settlement agreement. The Company is seeking enforcement of the settlement agreement and is seeking damages in an amount at least equal to the amounts paid to date to LDM under the settlement agreement, which approximates $900,000, as well as damages for lost income and business value as a result of LDM’s breach of the agreement.

In March 2015, we also initiated litigation against PDR Network, LLC in the United States District Court in the District of New Jersey as a result of PDR’s breach of the Master Services Agreement between the parties requiring PDR to exclusively use the Company’s eCoupon solution. The Company asserts that PDR’s acquisition of LDM and the use of the LDM network to distribute coupons by PDR violates the agreement between the parties and is seeking damages in an amount at least equal the amounts paid to date by the Company to LDM under the settlement agreement, which approximates $900,000, as well as damages for lost income and business value as a result of PDR’s actions.

In early 2014 the Company learned that Mr. Milton Wilpon (“Mr. Wilpon”) of New Jersey claimed to have obtained a default judgment for approximately $929,000 in the New Jersey Superior Court, Essex County (the “Judgment”) against a predecessor of the Company and was seeking to amend the Judgment to add the Company as a judgment debtor. The Judgment was entered in 2006 when the predecessor of the Company was a dormant shell company and the Judgment allegedly related to a settlement agreement that was breached in 2001 (the “Settlement Agreement”). The Company appeared in the action and filed a motion to vacate the Judgment on several grounds, including that it appeared that the Summons and Complaint were never properly served and that plaintiff had never filed an arbitration as was required by the Settlement Agreement. In September 2014, the Court granted the Company’s motion and vacated the Judgment in its entirety and dismissed the action.

In December 2014, the Company was served with a copy of a Demand for Arbitration filed by Mr. Wilpon relating to his claims under the Settlement Agreement. On February 24, 2015, the Company filed an appearance with the AAA objecting to the arbitration on several grounds, including (1) that claims arose in 2001 and are barred by the applicable statute of limitations; (2) plaintiff did not properly serve and file the demand for arbitration and (3) plaintiff has not followed the proper procedure for the appointment of an arbitrator as provided by the Settlement Agreement. The Company intends vigorously to oppose Mr. Wilpon’s claims.

Revenue-share contracts

The Company has contacts with various Electronic Health Records systems and ePrescribe platforms, whereby we agree to share a portion of the revenue we generate for eCoupons distributed through their networks. These contracts grant audit rights related to the payments to our partners, and in some cases would require us to pay for the audit if the audit determined there was an underpayment and the underpayment meets certain thresholds, such as 10%.

Restatement

6 Months Ended

12 Months Ended

Jun. 30, 2015

Dec. 31, 2014

Restatement [Abstract]

RESTATEMENT

NOTE 5 – RESTATEMENT

We restated our financial statements to correct the way we accounted for certain items related to stock based compensation, revenue share expense, and revenue recognition. The full impact of the restatement was reflected in the December 31, 2014 financial statements at the end of the year. The table below reflects the impact on the 2014 period reflected in this report.

The restated Consolidated Statement of Operations and Consolidated Statement of Cash Flows for the three and six months ended June 30, 2014, as applicable, is as follows:

Three months ended June 30, 2014					Previously
Financial Statement	Line Item	Corrected			Stated
Income statement	Revenue		1,426,808			1,454,214
Income statement	Cost of Sales	$	730,140		$	540,048
Income statement	Operating expenses		896,529			967,070
Income statement	Loss from operations	$	(199,861	)	$	(52,904	)
Income statement	Loss before income taxes	$	(199,638	)	$	(52,681	)
Income statement	Net loss	$	(199,638	)	$	(52,681	)

Six months ended June 30, 2014					Previously
Financial Statement	Line Item	Corrected			Stated
Income statement	Revenue		2,716,236			2,771,560
Income statement	Cost of Sales	$	1,291,551		$	1,038,858
Income statement	Operating expenses		2,386,747			2,439,028
Income statement	Loss from operations	$	(962,062	)	$	(706,326	)
Income statement	Loss before income taxes	$	(961,733	)	$	(705,996	)
Income statement	Net loss	$	(961,733	)	$	(705,996	)
Statement of cash flows	Net loss	$	(961,733	)	$	(705,996	)
Statement of cash flows	Stock and options issued for services	$	627,344		$	654,634
Statement of cash flows	Increase in accounts payable	$	203,714		$	173,889
Statement of cash flows	Decrease in revenue share payable	$	(311,776	)	$	(686,760	)
Statement of cash flows	Increase in deferred revenue	$	19,651		$	38,656

NOTE 17 – RESTATEMENT

The Company discovered and recorded items requiring it to restate its 2013 financial results, as well as its 2014 quarterly results, to correct the accounting for certain transactions contained therein. The restatement relates to unrecorded stock compensation related to investor relations and consulting services, unrecorded revenue share payables, and changes in revenue recognition, all occurring during the year ended December 31, 2013. The revenue recognition relates to promotional programs started in 2013 that were expected to be completed in 2013, but actually carried over into 2014.

The following items were restated in the 2013 Annual Financial Statements

Balance Sheet		Previously stated			Adjustments			Restated
Accounts receivable	$	1,566,964		$	(55,255	)	$	1,511,709
Revenue share payable	$	1,193,661		$	93,891		$	1,287,552
Deferred revenue	$	4,252		$	222,020		$	226,272
Additional paid in capital	$	8,726,708		$	148,477		$	8,875,155
Deferred stock compensation	$	(233,942	)	$	(36,520	)	$	(270,462	)
Accumulated deficit	$	(24,616,220	)	$	(483,137	)	$	(25,099,357	)

Statement of Operations
Revenue	$	4,957,016		$	(277,275	)	$	4,679,741
Revenue share expense	$	1,767,425		$	93,891		$	1,861,316
Operating expenses	$	2,973,990		$	111,701		$	3,085,691
Net income (loss)	$	215,847		$	(483,137	)	$	(267,290	)

Statement of Cash Flows
Net income (loss)	$	215,847		$	(483,137	)	$	(267,290	)
Stock options issued for services	$	19,547		$	75,451		$	94,998
Stock-based compensation	$	399,092		$	36,520		$	435,612
Changes in accounts receivable	$	(950,166	)	$	55,255		$	(894,911	)
Changes in revenue share payable	$	1,103,084		$	93,891		$	1,196,975
Changes in deferred revenue	$	(45,000	)	$	222,020		$	177,020

The following tables show the effect of the restatement on the unaudited quarterly information previously filed.

Period Ended September 30, 2013 (unaudited):

Balance Sheet	Previously stated			Adjustments			Restated

Revenue share payable	$	782,902		$	28,376		$	811,278
Deferred revenue	$	13,272		$	147,860		$	161,132
Additional paid in capital	$	8,449,271		$	148,477		$	8,597,748
Deferred stock compensation	$	(233,077	)	$	(54,780	)	$	(287,857	)
Accumulated deficit	$	(24,870,854	)	$	(270,207	)	$	(25,141,061	)

Statement of Operations
Three Months ended September 30, 2013
Revenue	$	1,373,029		$	(147,860	)	$	1,225,169
Revenue share expense	$	529,134		$	28,376		$	557,510
Operating expenses	$	982,504		$	93,971		$	1,076,475
Net income (loss)	$	(141,527	)	$	(270,207	)	$	(411,734	)
Nine Months ended September 30, 2013
Revenue	$	3,146,406		$	(147,860	)	$	2,998,546
Revenue share expense	$	1,264,059		$	28,376		$	1,292,435
Operating expenses	$	2,272,239		$	93,971		$	2,366,210
Net income (loss)	$	(389,716	)	$	(270,207	)	$	(659,923	)

Statement of Cash Flows
Net income (loss)	$	(389,716	)	$	(270,207	)	$	(659,923	)
Stock-based compensation	$	310,823		$	93,971		$	404,794
Changes in revenue share payable	$	649,825		$	28,376		$	678,201
Changes in deferred revenue	$	(35,980	)	$	147,860		$	111,880

Period Ended March 31, 2014 (unaudited):

Balance Sheet	Previously stated			Adjustments			Restated

Revenue share payable	$	797,725		$	167,880		$	965,605
Deferred revenue	$	168,714		$	268,807		$	437,521
Additional paid in capital	$	27,155,730		$	148,477		$	27,304,207
Deferred stock compensation	$	(454,409	)	$	(18,260	)	$	(472,669	)
Accumulated deficit	$	(25,269,535	)	$	(591,917	)	$	(25,861,452	)

Statement of Operations
Three Months ended March 31, 2014
Revenue	$	1,317,347		$	(27,919)		$	1,289,428
Revenue share expense	$	498,810		$	62,601		$	561,411
Operating expenses	$	1,471,598		$	18,260		$	1,489,858
Net income (loss)	$	(653,315	)	$	(108,780	)	$	(762,095	)

Statement of Cash Flows
Net income (loss)	$	(653,315	)	$	(108,780	)	$	(762,095	)
Stock-based compensation	$	361,957		$	18,260		$	380,217
Changes in revenue share payable	$	(395,935	)	$	62,601		$	(333,334	)
Changes in deferred revenue	$	164,462		$	27,919		$	192,381

Period Ended June 30, 2014 (unaudited):

Balance Sheet	Previously stated			Adjustments			Restated

Revenue share payable	$	506,901		$	366,088		$	872,989
Deferred revenue	$	42,908		$	258,270		$	301,178
Additional paid in capital	$	27,304,112		$	84,677		$	27,388,789
Accumulated deficit	$	(25,322,216	)	$	(738,674	)	$	26,060,890	)

Statement of Operations
Three Months ended June 30, 2014
Revenue	$	1,454,214		$	(27,206	)	$	1,427,008
Revenue share expense	$	540,048		$	190,092		$	730,140
Operating expenses	$	967,070		$	(70,541	)	$	896,529
Net income (loss)	$	(52,681	)	$	(146,757	)	$	(199,438	)

Six Months ended June 30, 2014
Revenue	$	2,771,560		$	(55,124	)	$	2,716,436
Revenue share expense	$	1,038,858		$	252,693		$	1,291,551
Operating expenses	$	2,439,028		$	(52,281	)	$	2,386,747
Net income (loss)	$	(705,996	)	$	(255,537	)	$	(961,533	)

Statement of Cash Flows
Net income (loss)	$	(705,996	)	$	(255,537	)	$	(961,533	)
Stock-based compensation	$	654,634		$	(52,281	)	$	602,353
Changes in revenue share payable	$	(686,760	)	$	252,693		$	(434,067	)
Changes in deferred revenue	$	38,656		$	55,124		$	93,780

Period Ended September 30, 2014(unaudited):

Balance Sheet	Previously stated			Adjustments			Restated

Revenue share payable	$	853,410		$	421,019		$	1,274,429
Deferred revenue	$	-0-		$	118,949		$	118,949
Additional paid in capital	$	28,398,825		$	84,677		$	28,483,502
Accumulated deficit	$	(25,716,530	)	$	(638,903	)	$	(26,355,433	)


Statement of Operations
Three Months ended September 30, 2014
Revenue	$	1,620,215		$	199,206		$	1,819,421
Revenue share expense	$	858,898		$	99,435		$	958,,333
Operating expenses	$	1,155,933		$	-0-		$	1,155,933
Net income (loss)	$	(394,314	)	$	99,771		$	(294,543	)

Nine Months ended September 30, 2014
Revenue	$	4,391,775		$	144,082		$	4,535,857
Revenue share expense	$	1,897,757		$	352,127		$	2,249,884
Operating expenses	$	3,594,961		$	(52,280	)	$	3,542,681
Net income (loss)	$	(1,100,310	)	$	(155,766	)	$	(1,256,076	)

Statement of Cash Flows
Net income (loss)	$	(1,100,310	)	$	(155,766	)	$	(1,256,076	)
Stock-based compensation	$	1,118,952		$	(52,280	)	$	(1,066,672	)
Changes in revenue share payable	$	(340,251	)	$	352,127		$	11,876
Changes in deferred revenue	$	(4,252	)	$	(144,082	)	$	(148,334	)

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Summary of Significant Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

Accounting Basis

The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting). The Company has adopted a December 31 fiscal year end.

Principles of Consolidation

The financial statements reflect the consolidated results of OptimizeRx Corporation (a Nevada corporation) and its wholly owned subsidiary OptimizeRx Corporation (a Michigan corporation). All material inter-company transactions have been eliminated in the consolidation.

Cash and Cash Equivalents

For purposes of the accompanying financial statements, the Company considers all highly liquid instruments with an initial maturity of three months or less to be cash equivalents.

Fair Value of Financial Instruments

The fair value of cash, accounts receivable, prepaid expenses, accounts payable, accounts payable – related party, accrued expenses and deferred revenue approximates the carrying amount of these financial instruments due to their short-term nature.

Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk.

In addition to defining fair value, the disclosure requirements around fair value establish a fair value hierarchy for valuation inputs which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

Level 2 – inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The Company’s stock options and warrants are valued using level 3 inputs.

The carrying value of the Company’s financial assets and liabilities which consist of cash, accounts receivable, prepaid expenses, patent rights, web development costs, accounts payable, accounts payable – related party, accrued expenses and deferred revenue are valued using level 1 inputs. The Company believes that the recorded values approximate their fair value due to the short maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, exchange or credit risks arising from these financial instruments.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. Because the Company’s customers are primarily large well capitalized companies, historically there has been very little bad debt expense. Bad debt expense was $0 for each of the years ended December 31, 2014 and 2013. The allowance for doubtful accounts was $0 as of both December 31, 2014 and 2013.

Property and Equipment

The capital assets are being depreciated over their estimated useful lives of three to seven years using the straight-line method of depreciation for book purposes.

Revenue Recognition and Revenue Share Expense

Revenue is recognized when it is earned. Revenues are generated from our SampleMD activities in which we deliver eCoupons and eVouchers through a distribution network of ePrescribers and Electronic Health Record technology providers (channel partners), or from reselling services that complement our business for other of our partners.

We recognize setup fees that are required for integrating client offerings and campaigns into the SampleMD content delivery system and network upon completion of the setup and launch of the client’s campaign within the SampleMD system. As the eCoupons and or eVouchers are distributed through the SampleMD platform and network of channel partners (a transaction), these transactions are recorded and revenue is recognized at the time of distribution. Revenue for transactions can be realized based on a price per distribution or a price per redemption depending on the client contract. Additionally, the company also recognizes revenue for providing program performance reporting and maintenance, either by the company directly delivering reports or by providing access to its online reporting portal that the client can utilize. These fees are charged monthly and recognized as recurring monthly revenue.

The company on occasion has also resold products and or services that are available through our channel partners, and that is complementary to our core businesses and client base. In these instances net revenue is recognized based on the commission based revenue split that the company receives.

Based on the volume of transactions that are delivered through our channel partner network, we provide a revenue share to compensate the partner for their promotion of the campaign. Revenue shares are a negotiated percentage of the transaction fees and can also be specific to special considerations and campaigns. In addition, we pay revenue share to PDR/LDM as a result of a 2014 legal settlement in an amount equal to the greater of 10% of eCoupon revenues generated or $0.37 per eCoupon distributed.

Income Taxes

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the depreciable lives of such assets and the allowance for doubtful accounts receivable. Actual results could differ from these estimates.

Concentration of Credit Risks

The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties.

Research and Development

The Company expenses research and development expenses as incurred. Our research efforts are focused on understanding the market dynamics that have the potential to affect the business in both the short and long term. Our primary goal is to help patients better afford and access the medicines their doctor prescribes, as well as other healthcare products and services they need. Based on this, the Company continually seeks better ways to meet this mission through improved technology, better user experiences and new ways to engage industries to provide new support for patients needing their products, as well seeking new services and solutions to offer.

Share-based Payments

The Company uses the fair value method to account for stock-based compensation. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered. The fair value of each award is estimated on the date of each grant. For restricted stock the fair market value is based on the market value of the stock granted on the date of the grant. For options, it is estimated using the Black Scholes option pricing model that uses the assumptions noted in the following table. Estimated volatilities are based on the historical volatility of the Company’s stock over the same period as the expected term of the options. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The Company uses historical data to estimate option exercise behavior and to determine this term. The risk free rate used is based on the U.S. Treasury yield curve in effect at the time of the grant using a time period equal to the expected option term. The Company has never paid dividends and does not expect to pay any dividends in the future.

	2014			2013

Expected dividend yield		0	%		0	%
Risk free interest rate		0.90%-1.44%			0.79%-1.42%
Expected option term		3.5 years			5.0 years
Turnover/forfeiture rate		0	%		0	%
Expected volatility		117% - 138%			155% - 171%

The Black-Scholes option valuation model and other existing models were developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. These option valuation models require the input of, and are highly sensitive to, subjective assumptions including the expected stock price volatility. OptimizerRx’s stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions could materially affect the fair value estimate.

Loss Per Common and Common Equivalent Share

The computation of basic earnings per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus common stock equivalents which would arise from the exercise of warrants outstanding using the treasury stock method and the average market price per share during the year. Options, warrants and convertible preferred stock have not been included in the diluted earnings per share calculation for either year since their effect is anti-dilutive.

Impairment of Long-Lived Assets

The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.

Recently Issued Accounting Guidance

The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Common Stock	6 Months Ended	12 Months Ended
Common Stock	Jun. 30, 2015	Dec. 31, 2014
Equity [Abstract]
COMMON STOCK	NOTE 2 – STOCKHOLDERS EQUITY In January 2015, we issued 12,500 shares of common stock to outside Directors in connection with our Director Compensation plan, which calls for issuance of 6,250 shares per quarter for each Director. Those shares were recorded as stock payable at December 31, 2014. In addition, we recorded an additional 12,500 shares, valued at $16,375 as stock payable at March 31, 2015 for shares to be issued in April 2015 and 12,500 shares, valued at $13,375 were issued in June 2015 for the second quarter payment. In February 2015, we entered into a capital markets advisory agreement covering a one year period, which called for 90,000 shares of common stock to be issued as compensation. These shares were valued at $112,500 and are being amortized to expense over the period of service. 45,000 of these shares were issued in March 2015, with the balance to be issued in August 2015. The agreement was terminated in July 2015, effective in August, and the remaining 45,000 shares will not be issued. The total expense to be recognized will be $56,250 and is being amortized over the period the agreement is in effect. In March 2014, we entered into a securities purchase agreement, pursuant to which we sold 8,333,333 shares of our common stock for $1.20 per share, or gross proceeds of $10,000,000. Placement agents in the offering received commissions equal to approximately 9.7% of gross proceeds, for an aggregate commission of approximately $970,000, including reimbursements for their reasonable out of pocket expenses. Placement agents also received warrants to purchase up to 804,139 shares of our common stock with an exercise price of $1.20 per share and a term of 5 years. The warrants were valued at $1,110,211, have been recorded as equity issuance costs, and were registered on a registration statement that went effective May 28, 2014. In addition to the warrants to placement agents, we also paid cash bonuses of $240,000 to three executive officers, agreed to issue 200,000 shares to three executive officers, and issued 150,000 shares to a consultant, in connection with the equity raise. The stock was valued based on the fair market value on the grant date, which was $630,000 in total. These amounts have been recorded as equity issuance costs, resulting in total equity issuance costs of $2.95 million. The 200,000 shares for the three executive officers have not been issued, but are recorded as stock payable and can be requested by the executive officers at any time. We used the net proceeds of the offering to exercise the securities redemption option agreement, as amended, with Vicis Capital Master Fund that provided us with an option to purchase all of the outstanding shares and derivative securities held by Vicis for total payment of $6,000,000. The shares and derivative securities included the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Common Stock, and warrants to purchase shares of common stock held by Vicis in the Company. The balance of the net proceeds were used for working capital purposes. In January 2014, an executive officer exercised 500,000 stock warrants using the cashless exercise feature included in the warrants. In exchange for the 500,000 warrants, 410,348 shares of common stock were issued. In June 2015, we agreed to grant 197,605 fully vested shares of our common stock to two executive officers as bonuses. These shares have not been issued, but are recorded as stock payable and can be requested by the officers at any time. In February 2014, we agreed to grant 337,500 shares of our common stock, half of which vested immediately and half of which vested in August 2014, to two executive officers as bonuses based on their efforts to recapitalize the company to secure approximately $3 million in working capital while reducing fully diluted shares by approximately 7 million shares. These shares have not been issued, but are recorded as stock payable and can be requested by the officers at any time.	NOTE 9 – COMMON STOCK OptimizeRx Corporation has 500,000,000 shares of $.001 par value common stock authorized as of December 31, 2014. There were 22,867,319 and 14,817,496 common shares issued and outstanding at December 31, 2014 and 2013, respectively. On June 1, 2013, the Company entered into a consulting agreement with North Coast Advisors, Inc. for various services. The Company agreed to issue 20,000 shares of common stock as of the date of the contract. The Company also agreed to issue an additional 20,000 shares every six months in alignment with the agreement renewal up to the two years of the agreement. The first 20,000 shares were valued at the Company’s common stock closing price as of the date of the contract, which was $1.945/share; and the second 20,000 shares were valued at the Company’s common stock closing price of $1.50/share on the date of issuance, and have been expensed. An additional 10,000 shares were issued in 2014 before the agreement was terminated by the Company. The 2014 shares were valued at $1.85, the closing price of the Company’s common stock on the date of issuance. On June 10, 2013, the Company entered into a capital markets advisory agreement with Taglich Brothers, Inc. for various services. The agreement covered a one year period and the Company agreed to issue 44,000 shares of common stock to Taglich over the term of the agreement. The shares were valued at $1.66, the closing price of the stock on the date of the agreement and were written off over the term of the agreement. The shares were issued in June 2014 upon expiration of the contract. On September 20, 2013, the Company entered into a separation agreement that included post-employment consulting services with the former CEO of the Company. The Company agreed to issue 500,000 shares of common stock, 250,000 shares immediately and 250,000 by January 1, 2014. The shares have been issued and the Company recognized the entire issuance in the December 31, 2013 shares outstanding. The shares were valued at $505,000 and $174,808 of that amount remained as deferred stock compensation as of December 31, 2013, but has been fully amortized to expenses as of December 31, 2014. In March 2014, the Company entered into a securities purchase agreement, pursuant to which the Company sold 8,333,333 shares of the Company’s common stock for $1.20 per share, or gross proceeds of $10,000,000. Placement agents in the offering received commissions equal to approximately 9.7% of gross proceeds, for an aggregate commission of approximately $970,000, including reimbursements for their reasonable out of pocket expenses. Placement agents also received warrants to purchase up to 804,139 shares of the Company's common stock with an exercise price of $1.20 per share and a term of 5 years. The warrants were valued at $1,110,211, have been recorded as equity issuance costs, and were registered on a registration statement dated May 28, 2014. In addition to the warrants to placement agents, the Company also paid cash bonuses of $240,000 to three executive officers, agreed to issue 200,000 shares to three executive officers, and issued 150,000 shares to a consultant, in connection with the equity raise. The stock was valued based on the fair market value on the grant date, which was $630,000 in total. These amounts have been recorded as equity issuance costs, resulting in total equity issuance costs of $2.95 million. The 200,000 shares for the three executive officers have not been issued, but are recorded as stock payable and can be requested by the respective officers at any time. The Company used the net proceeds of the offering to exercise the securities redemption option agreement, as amended, with Vicis Capital Master Fund that provided the Company with an option to purchase all of the outstanding shares and derivative securities held by Vicis for total payment of $6,000,000. The shares and derivative securities included the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Common Stock, and warrants to purchase shares of common stock held by Vicis in the Company. The balance of the net proceeds was used for working capital purposes. In January 2014, an executive officer exercised 500,000 stock warrants using the cashless exercise feature included in the warrants. In exchange for the 500,000 warrants, 410,348 shares of common stock were issued. In October 2014, a consultant exercised 50,000 stock warrants using the cashless exercise feature included in the warrants. In exchange for the 50,000 warrants, 35,417 shares of common stock were issued. In February 2014, the Company agreed to grant 337,500 shares of common stock, half of which vested immediately and half of which vested in August 2014, to two executive officers as bonuses based on their efforts to recapitalize the company to secure approximately $3 million in working capital while reducing potential fully diluted shares by approximately 7 million shares. Stock-based compensation related to these bonuses was $570,375 during the year ended December 31, 2014. These shares have not yet been issued and are recorded as stock payable, but can be requested by the officers at any time. In 2014, the Company adopted a Director Compensation plan for outside Directors. In connection with this plan, 19,565 shares were granted with a total value of $23,166. A total of 7,065 shares were issued in 2014 and 12,500 shares were included in stock payable at December 31, 2014 and issued in January 2015.

- Definition

+ References

+ Details

Preferred Stock

12 Months Ended

Dec. 31, 2014

Equity [Abstract]

PREFERRED STOCK

NOTE 10 – PREFERRED STOCK

Series A Preferred

During the year ended December 31, 2008, 35 preferred shares were issued for $3,500,000. Issuance costs totaled $515,000 resulting in net proceeds of $2,985,000. The 35 shares are convertible to 3,500,000 shares of common stock and bear a 10% cumulative dividend. In addition, there was a warrant issued to purchase 6,000,000 shares of common stock at an exercise price of $2 for a period of seven years.

The holders of the preferred stock are entitled to semi-annual dividends payable on the stated value of the Series A preferred stock at a rate of 10% per annum, which shall be cumulative, and accrue daily from the issuance date. The dividends may be paid in cash or shares of the Company's common stock at management’s discretion. If after the conversion eligibility date, the market price for the common stock for any ten consecutive trading days in which the stock trades for over $2 per share and trading exceeds 100,000 shares per day, the preferred shareholders can be required to convert their shares to common stock. Each share of Series A preferred stock shall also be convertible at the option of the holder into that number of shares of common stock of the Company at the stated value of such share at a $1 conversion price.

The holder could cause this conversion at the time the shares are eligible for resale by the holder. The conversion price is subject to adjustment as hereinafter provided, at any time, or from time to time upon the terms and in the manner hereinafter set forth in the shareholder agreement. There is no conversion expiration date, however, the holder must provide 30 days notice for the registration of the conversion.

On May 12, 2010, the Company’s Board declared and issued 236,598 common shares as payment for all cumulative and current semi-annual dividends. On November 16, 2010, the Company’s Board declared and issued 173,922 common shares for its semi-annual dividend payment. On March 25, 2011, the Company’s Board declared and issued 176,768 common shares for its semi-annual dividend payment. On September 21, 2011, the Company's Board declared and issued 156,306 common shares for its semi-annual dividend payment. The Company has undeclared dividends that were due in February and September 2012 totaling $350,000 and undeclared dividends of $350,000 that were due in February and September 2013 for a total undeclared amount of $700,000 as of December 31, 2013.

As described in greater detail in Note 10, all of the Series A Preferred shares were redeemed in 2014.

Series B Preferred

During the year ended December 31, 2010, 15 preferred shares were issued for $1,500,000. The 15 shares are convertible to 1,000,000 shares of common stock and bear a 10% cumulative dividend. In addition, there was a warrant issued to purchase 3,000,000 shares of common stock at an exercise price of $3 for a period of seven years.

The preferred stock was issued for $1,500,000 less associated issuance costs of $350,000 for net proceeds of $1,150,000. Additionally, 3,000,000 common stock warrants were issued with the preferred stock. Based on the fair values of the preferred stock and common stock warrants on the issue date, $341,100 was allocated to preferred stock and $1,158,900 was allocated to the common stock warrants. Equity issuance costs of $350,000 were allocated to the preferred stock.

During the quarter ended September 30, 2011, 15 preferred shares were issued to an investor for $1,500,000. The 15 shares are convertible to 1,000,000 shares of common stock and bear a 10% cumulative dividend. In addition, there was a warrant issued to purchase 1,000,000 shares of common stock at an exercise price of $3 for a period of seven years. Based on the fair values of the preferred stock and common stock warrants on the issue date, $855,460 was allocated to preferred stock and $644,540 was allocated to the common stock warrants. See Note 12.

The holders of the preferred stock are entitled to semi-annual dividends payable on the stated value of the Series B preferred stock at a rate of 10% per annum, which shall be cumulative, and accrue daily from the issuance date. The dividends may be paid in cash or shares of the Company's common stock at management’s discretion. If after the conversion eligibility date, the market price for the common stock for any ten consecutive trading days in which the stock trades for over $2 per share and trading exceeds 100,000 shares per day, the preferred shareholders can be required to convert their shares to common stock. Each share of Series B preferred stock shall also be convertible at the option of the holder into that number of shares of common stock of the Company at the stated value of such share at a $1.50 conversion price.

On March 25, 2011, the Company’s Board declared and issued 75,758 common shares for its semi-annual dividend payment. On September 21, 2011, the Company's Board declared and issued 66,988 common shares for its semi-annual dividend payment. The Company has undeclared dividends that were due in February and September 2012 totaling $150,000 and undeclared dividends of $150,000 that were due in February and September 2013 for a total undeclared amount of $300,000 as of December 31, 2013.

As described in greater detail in Note 9, all of the Series B Preferred shares were redeemed in 2014.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2014

Summary of Significant Accounting Policies [Abstract]

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

Accounting Basis

Principles of Consolidation

Cash and Cash Equivalents

For purposes of the accompanying financial statements, the Company considers all highly liquid instruments with an initial maturity of three months or less to be cash equivalents.

Fair Value of Financial Instruments

Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

Accounts Receivable and Allowance for Doubtful Accounts

Property and Equipment

The capital assets are being depreciated over their estimated useful lives of three to seven years using the straight-line method of depreciation for book purposes.

Revenue Recognition and Revenue Share Expense

Income Taxes

Use of Estimates

Concentration of Credit Risks

Research and Development

Share-based Payments

	2014			2013

Expected dividend yield		0	%		0	%
Risk free interest rate		0.90%-1.44%			0.79%-1.42%
Expected option term		3.5 years			5.0 years
Turnover/forfeiture rate		0	%		0	%
Expected volatility		117% - 138%			155% - 171%

Loss Per Common and Common Equivalent Share

Impairment of Long-Lived Assets

Recently Issued Accounting Guidance

The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Restatement (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2015

Dec. 31, 2014

Restatement [Abstract]

Schedule of restatement

Three months ended June 30, 2014					Previously
Financial Statement	Line Item	Corrected			Stated
Income statement	Revenue		1,426,808			1,454,214
Income statement	Cost of Sales	$	730,140		$	540,048
Income statement	Operating expenses		896,529			967,070
Income statement	Loss from operations	$	(199,861	)	$	(52,904	)
Income statement	Loss before income taxes	$	(199,638	)	$	(52,681	)
Income statement	Net loss	$	(199,638	)	$	(52,681	)

Six months ended June 30, 2014					Previously
Financial Statement	Line Item	Corrected			Stated
Income statement	Revenue		2,716,236			2,771,560
Income statement	Cost of Sales	$	1,291,551		$	1,038,858
Income statement	Operating expenses		2,386,747			2,439,028
Income statement	Loss from operations	$	(962,062	)	$	(706,326	)
Income statement	Loss before income taxes	$	(961,733	)	$	(705,996	)
Income statement	Net loss	$	(961,733	)	$	(705,996	)
Statement of cash flows	Net loss	$	(961,733	)	$	(705,996	)
Statement of cash flows	Stock and options issued for services	$	627,344		$	654,634
Statement of cash flows	Increase in accounts payable	$	203,714		$	173,889
Statement of cash flows	Decrease in revenue share payable	$	(311,776	)	$	(686,760	)
Statement of cash flows	Increase in deferred revenue	$	19,651		$	38,656

The following items were restated in the 2013 Annual Financial Statements

Balance Sheet		Previously stated			Adjustments			Restated
Accounts receivable	$	1,566,964		$	(55,255	)	$	1,511,709
Revenue share payable	$	1,193,661		$	93,891		$	1,287,552
Deferred revenue	$	4,252		$	222,020		$	226,272
Additional paid in capital	$	8,726,708		$	148,477		$	8,875,155
Deferred stock compensation	$	(233,942	)	$	(36,520	)	$	(270,462	)
Accumulated deficit	$	(24,616,220	)	$	(483,137	)	$	(25,099,357	)

Statement of Operations
Revenue	$	4,957,016		$	(277,275	)	$	4,679,741
Revenue share expense	$	1,767,425		$	93,891		$	1,861,316
Operating expenses	$	2,973,990		$	111,701		$	3,085,691
Net income (loss)	$	215,847		$	(483,137	)	$	(267,290	)

Statement of Cash Flows
Net income (loss)	$	215,847		$	(483,137	)	$	(267,290	)
Stock options issued for services	$	19,547		$	75,451		$	94,998
Stock-based compensation	$	399,092		$	36,520		$	435,612
Changes in accounts receivable	$	(950,166	)	$	55,255		$	(894,911	)
Changes in revenue share payable	$	1,103,084		$	93,891		$	1,196,975
Changes in deferred revenue	$	(45,000	)	$	222,020		$	177,020

Period Ended September 30, 2013 (unaudited):

Balance Sheet	Previously stated			Adjustments			Restated

Revenue share payable	$	782,902		$	28,376		$	811,278
Deferred revenue	$	13,272		$	147,860		$	161,132
Additional paid in capital	$	8,449,271		$	148,477		$	8,597,748
Deferred stock compensation	$	(233,077	)	$	(54,780	)	$	(287,857	)
Accumulated deficit	$	(24,870,854	)	$	(270,207	)	$	(25,141,061	)

Statement of Operations
Three Months ended September 30, 2013
Revenue	$	1,373,029		$	(147,860	)	$	1,225,169
Revenue share expense	$	529,134		$	28,376		$	557,510
Operating expenses	$	982,504		$	93,971		$	1,076,475
Net income (loss)	$	(141,527	)	$	(270,207	)	$	(411,734	)
Nine Months ended September 30, 2013
Revenue	$	3,146,406		$	(147,860	)	$	2,998,546
Revenue share expense	$	1,264,059		$	28,376		$	1,292,435
Operating expenses	$	2,272,239		$	93,971		$	2,366,210
Net income (loss)	$	(389,716	)	$	(270,207	)	$	(659,923	)

Statement of Cash Flows
Net income (loss)	$	(389,716	)	$	(270,207	)	$	(659,923	)
Stock-based compensation	$	310,823		$	93,971		$	404,794
Changes in revenue share payable	$	649,825		$	28,376		$	678,201
Changes in deferred revenue	$	(35,980	)	$	147,860		$	111,880

Period Ended March 31, 2014 (unaudited):

Three Months ended March 31, 2014

Balance Sheet	Previously stated			Adjustments			Restated

Revenue share payable	$	797,725		$	167,880		$	965,605
Deferred revenue	$	168,714		$	268,807		$	437,521
Additional paid in capital	$	27,155,730		$	148,477		$	27,304,207
Deferred stock compensation	$	(454,409	)	$	(18,260	)	$	(472,669	)
Accumulated deficit	$	(25,269,535	)	$	(591,917	)	$	(25,861,452	)

Statement of Operations

Revenue	$	1,317,347		$	(27,919)		$	1,289,428
Revenue share expense	$	498,810		$	62,601		$	561,411
Operating expenses	$	1,471,598		$	18,260		$	1,489,858
Net income (loss)	$	(653,315	)	$	(108,780	)	$	(762,095	)

Statement of Cash Flows
Net income (loss)	$	(653,315	)	$	(108,780	)	$	(762,095	)
Stock-based compensation	$	361,957		$	18,260		$	380,217
Changes in revenue share payable	$	(395,935	)	$	62,601		$	(333,334	)
Changes in deferred revenue	$	164,462		$	27,919		$	192,381

Period Ended June 30, 2014 (unaudited):

Balance Sheet	Previously stated			Adjustments			Restated

Revenue share payable	$	506,901		$	366,088		$	872,989
Deferred revenue	$	42,908		$	258,270		$	301,178
Additional paid in capital	$	27,304,112		$	84,677		$	27,388,789
Accumulated deficit	$	(25,322,216	)	$	(738,674	)	$	26,060,890	)

Statement of Operations
Three Months ended June 30, 2014
Revenue	$	1,454,214		$	(27,206	)	$	1,427,008
Revenue share expense	$	540,048		$	190,092		$	730,140
Operating expenses	$	967,070		$	(70,541	)	$	896,529
Net income (loss)	$	(52,681	)	$	(146,757	)	$	(199,438	)

Six Months ended June 30, 2014
Revenue	$	2,771,560		$	(55,124	)	$	2,716,436
Revenue share expense	$	1,038,858		$	252,693		$	1,291,551
Operating expenses	$	2,439,028		$	(52,281	)	$	2,386,747
Net income (loss)	$	(705,996	)	$	(255,537	)	$	(961,533	)

Statement of Cash Flows
Net income (loss)	$	(705,996	)	$	(255,537	)	$	(961,533	)
Stock-based compensation	$	654,634		$	(52,281	)	$	602,353
Changes in revenue share payable	$	(686,760	)	$	252,693		$	(434,067	)
Changes in deferred revenue	$	38,656		$	55,124		$	93,780

Period Ended September 30, 2014(unaudited):

Balance Sheet	Previously stated			Adjustments			Restated

Revenue share payable	$	853,410		$	421,019		$	1,274,429
Deferred revenue	$	-0-		$	118,949		$	118,949
Additional paid in capital	$	28,398,825		$	84,677		$	28,483,502
Accumulated deficit	$	(25,716,530	)	$	(638,903	)	$	(26,355,433	)


Statement of Operations
Three Months ended September 30, 2014
Revenue	$	1,620,215		$	199,206		$	1,819,421
Revenue share expense	$	858,898		$	99,435		$	958,,333
Operating expenses	$	1,155,933		$	-0-		$	1,155,933
Net income (loss)	$	(394,314	)	$	99,771		$	(294,543	)

Nine Months ended September 30, 2014
Revenue	$	4,391,775		$	144,082		$	4,535,857
Revenue share expense	$	1,897,757		$	352,127		$	2,249,884
Operating expenses	$	3,594,961		$	(52,280	)	$	3,542,681
Net income (loss)	$	(1,100,310	)	$	(155,766	)	$	(1,256,076	)

Statement of Cash Flows
Net income (loss)	$	(1,100,310	)	$	(155,766	)	$	(1,256,076	)
Stock-based compensation	$	1,118,952		$	(52,280	)	$	(1,066,672	)
Changes in revenue share payable	$	(340,251	)	$	352,127		$	11,876
Changes in deferred revenue	$	(4,252	)	$	(144,082	)	$	(148,334	)

Stockholders Equity (Details) - USD ($)	1 Months Ended						3 Months Ended	6 Months Ended	12 Months Ended
Stockholders Equity (Details) - USD ($)	Jul. 31, 2015	Feb. 28, 2015	Jan. 31, 2015	Oct. 31, 2014	Mar. 31, 2014	Jan. 31, 2014	Jun. 30, 2015	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2015	Feb. 28, 2014
Stockholders Equity (Textual)
Called for issuance of shares, values									$ (6,000,000)
Additional shares issued, value										$ 0
Common stock issued for equity issuance costs								$ 630,000	630,000
Employee bonus, Share		$ 337,500							$ 337,500
Employee bonus, Value									570,375
Additional working capital									$ 3,000,000			$ 3,000,000
Fully diluted shares									7,000,000			7,000,000
Equity issuance cost								2,950,000	$ 2,950,000
Warrants exercised, number of shares				50,000					500,000
Capital Markets Advisory Agreement [Member]
Stockholders Equity (Textual)
Called for issuance of shares		90,000
Additional shares issued											45,000
Called for issuance of shares, values		$ 112,500
Subsequent Event [Member] \| Capital Markets Advisory Agreement [Member]
Stockholders Equity (Textual)
Number of shares not be issued	$ 45,000
Called for issuance of shares, values	$ 56,250
Securities Purchase Agreement [Member]
Stockholders Equity (Textual)
Sale of comman stock shares					8,333,333
Sale of common stock value					$ 10,000,000
Sale of stock price per share					$ 1.20
Placement agents [Member]
Stockholders Equity (Textual)
Warrant exercise price period					5 years
Commissions percentage					9.70%
Commissions					$ 970,000
Purchase of warrants					804,139
Warrants, value					$ 1,110,211
Exercise price					$ 1.20
Three officers [Member]
Stockholders Equity (Textual)
Additional shares issued					200,000
Employee Bonus					$ 240,000
Consultant [Member]
Stockholders Equity (Textual)
Additional shares issued					150,000
Vicis Member]
Stockholders Equity (Textual)
Debt redemption, amount									$ 6,000,000
Officer [Member]
Stockholders Equity (Textual)
Additional shares issued						410,348
Additional shares issued						410,348
Warrants exercised, number of shares						500,000
Outside director [Member]
Stockholders Equity (Textual)
Called for issuance of shares			6,250
Additional shares issued			12,500						7,065
Debt redemption, amount							$ 6,000,000	$ 6,000,000
Additional shares issued							12,500	12,500
Additional shares issued, value							$ 16,375	$ 13,375
Two Officers [Member]
Stockholders Equity (Textual)
Employee bonus, Share								$ 197,605

Restatement (Details) - USD ($)	3 Months Ended					6 Months Ended		9 Months Ended		12 Months Ended
Restatement (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Jun. 30, 2015	Jun. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Accounts receivable	$ 1,918,419			$ 965,605	$ 811,278	$ 1,918,419			$ 811,278	$ 2,100,381	$ 1,511,709
Revenue share payable	1,190,995	$ 1,274,429	$ 872,989			1,190,995	$ 872,989	$ 1,274,429		1,502,761	1,287,552
Deferred revenue	336,213	118,949	301,178	437,521	161,132	336,213	301,178	118,949	161,132	120,130	226,272
Additional paid-in-capital	27,806,253	28,483,502	27,388,789	27,304,207	8,597,748	27,806,253	27,388,789	28,483,502	8,597,748	27,595,609	8,875,155
Deferred stock compensation	18,750			(472,669)	(287,857)	18,750			(287,857)		270,462
Accumulated deficit	(26,393,176)	(26,355,433)	(26,060,890)	(25,861,452)	(25,141,061)	(26,393,176)	(26,060,890)	(26,355,433)	(25,141,061)	(26,124,750)	(25,099,357)
Income Statement [Abstract]
Revenues	1,705,457	1,819,421	1,426,808	1,289,428	1,225,169	3,193,010	2,716,236	4,535,857	2,998,546	6,502,962	4,679,741
Cost of Sales			730,140				1,291,551
Operating expenses	980,659	1,155,933	896,529	1,489,858	1,076,475	1,823,269	2,386,747	3,542,681	2,366,210	4,307,756	3,085,961
Loss from operations	(157,529)		(199,861)			(269,027)	(962,062)			(1,026,328)	(267,536)
Loss before income taxes	(157,225)		(199,638)			(268,426)	(961,733)			(1,025,393)	(267,290)
Revenue share expense	882,327	958,333	730,140	561,411	557,510	1,638,768	1,291,551	2,249,884	1,292,435	3,221,534	1,861,316
Net loss	(157,225)	(294,543)	(199,638)	(762,095)	(411,734)	(268,426)	(961,733)	(1,256,076)	(659,923)	(1,025,393)	(267,290)
Statement of Cash Flows [Abstract]
Net loss	$ (157,225)	(294,543)	(199,638)	(762,095)	(411,734)	(268,426)	(961,733)	(1,256,076)	(659,923)	(1,025,393)	(267,290)
Stock and options issued for services						361,062	627,354			272,804	94,998
Increase in accounts payable						(181,962)	(302,202)			588,672	894,911
Decrease in revenue share payable							(311,776)
Increase in deferred revenue				192,381		216,083	19,651	(148,334)	111,880	(106,142)	177,020
Share-based Compensation				380,217		110,039	170,611	(1,066,672)	404,794	899,438	435,612
Revenue share payable				(333,334)		$ (311,766)	(414,563)	11,876	678,201	$ 215,210	1,196,975
Previously stated [Member]
Statement of Financial Position [Abstract]
Accounts receivable				797,725	782,902				782,902		1,566,964
Revenue share payable		853,410	506,901				506,901	853,410			1,193,661
Deferred revenue			42,908	168,714	13,272		42,908		13,272		4,252
Additional paid-in-capital		28,398,825	27,304,112	27,155,730	8,449,271		27,304,112	28,398,825	8,449,271		8,726,708
Deferred stock compensation				(454,409)	(233,077)				(233,077)		(233,942)
Accumulated deficit		(25,716,530)	(25,322,216)	(25,269,535)	(24,870,854)		(25,322,216)	(25,716,530)	(24,870,854)		(24,616,220)
Income Statement [Abstract]
Revenues		1,620,215	1,454,214	1,317,347	1,373,029		2,771,560	4,391,775	3,146,406		4,957,016
Cost of Sales			540,048				1,038,858
Operating expenses		1,155,933	967,070	1,471,598	982,504		2,439,028	3,594,961	2,272,239		2,973,990
Loss from operations			(52,904)				(706,326)
Loss before income taxes			(52,681)				(705,996)
Revenue share expense		858,898	540,048	498,810	529,134		1,038,858	1,897,757	1,264,059		1,767,425
Net loss		(394,314)	(52,681)	(653,315)	(141,527)		(705,996)	(1,100,310)	(389,716)		215,847
Statement of Cash Flows [Abstract]
Net loss		(394,314)	(52,681)	(653,315)	(141,527)		(705,996)	(1,100,310)	(389,716)		215,847
Stock and options issued for services							654,634				19,547
Increase in accounts payable							173,889				(950,166)
Decrease in revenue share payable							(686,760)
Increase in deferred revenue				164,462			38,656	(4,252)	(35,980)		(45,000)
Share-based Compensation				361,957			654,634	1,118,952	310,823		399,092
Revenue share payable				(395,935)			(686,760)	(340,251)	649,825		1,103,084
Adjustments [Member]
Statement of Financial Position [Abstract]
Accounts receivable				167,880	28,376				28,376		(55,255)
Revenue share payable		421,019	366,088				366,088	421,019			93,891
Deferred revenue		118,949	258,270	268,807	147,860		258,270	118,949	147,860		222,020
Additional paid-in-capital		84,677	84,677	148,477	148,477		84,677	84,677	148,477		148,477
Deferred stock compensation				(18,260)	(54,780)				(54,780)		(36,520)
Accumulated deficit		(638,903)	(738,674)	(591,917)	(270,207)		(738,674)	(638,903)	(270,207)		(483,137)
Income Statement [Abstract]
Revenues		199,206	(27,206)	(27,919)	(147,860)		(55,124)	144,082	(147,860)		(277,275)
Operating expenses			(70,541)	18,260	93,971		(52,281)	(52,280)	93,971		111,701
Revenue share expense		99,435	190,092	62,601	28,376		252,693	352,127	28,376		93,891
Net loss		99,771	(146,757)	(108,780)	(270,207)		(255,537)	(155,766)	(270,207)		(483,137)
Statement of Cash Flows [Abstract]
Net loss		$ 99,771	$ (146,757)	(108,780)	$ (270,207)		(255,537)	(155,766)	(270,207)		(483,137)
Stock and options issued for services											75,451
Increase in accounts payable											55,255
Increase in deferred revenue				27,919			55,124	(144,082)	147,860		222,020
Share-based Compensation				18,260			(52,281)	(52,280)	93,971		36,520
Revenue share payable				$ 62,601			$ 252,693	$ 352,127	$ 28,376		$ 93,891

Common Stock (Details) - USD ($)	1 Months Ended				6 Months Ended	12 Months Ended
Common Stock (Details) - USD ($)	Feb. 28, 2015	Oct. 31, 2014	Mar. 31, 2014	Jan. 31, 2014	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2015	Jan. 31, 2015	Feb. 28, 2014	Jan. 02, 2014	Sep. 30, 2013	Sep. 20, 2013	Jun. 10, 2013	Jun. 01, 2013
Class of Stock [Line Items]
Common stock, shares authorized					500,000,000	500,000,000	500,000,000
Common stock par value					$ 0.001	$ 0.001	$ 0.001
Common stock, shares issued		35,417			22,949,819	22,867,319	14,817,496
Common stock, shares outstanding					22,949,819	22,867,319	14,817,496
Common stock value, Issued					$ 22,950	$ 22,867	$ 14,817
Deferred stock compensation			$ (472,669)		18,750		270,462					$ (287,857)
Gross proceeds						41,667	$ 105,420
Common stock issued for equity issuance costs					630,000	630,000
Employee bonus, Share	$ 337,500					$ 337,500
Employee bonus, Value						570,375
Additional working capital						$ 3,000,000				$ 3,000,000
Fully diluted shares						7,000,000				7,000,000
Equity issuance cost					2,950,000	$ 2,950,000
Shares granted						387,500	2,175,000
Warrants exercised, number of shares		50,000				500,000
Consulting Agreement [Member]
Class of Stock [Line Items]
Common stock par value															$ 1.945
Common stock, shares issued															20,000
Additional shares issued						10,000									20,000
Shares Issued, per share value						$ 1.85									$ 1.50
Capital Markets Advisory Agreement [Member]
Class of Stock [Line Items]
Common stock par value														$ 1.66
Common stock, shares issued														44,000
Additional shares issued								45,000
Separation Agreement [Member]
Class of Stock [Line Items]
Common stock, shares issued											250,000		250,000
Common stock value, Issued													$ 505,000
Deferred stock compensation													$ 174,808
Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Sales of common stock			8,333,333
Warrant exercise price period			5 years
Sale of stock price per share			$ 1.20
Gross proceeds			$ 10,000,000
Placement agents [Member]
Class of Stock [Line Items]
Warrant exercise price period			5 years
Commissions percentage			9.70%
Commissions			$ 970,000
Purchase of warrants			804,139
Warrants, value			$ 1,110,211
Three executive officers [Member]
Class of Stock [Line Items]
Additional shares issued			200,000
Employee Bonus			$ 240,000
Consultant [Member]
Class of Stock [Line Items]
Additional shares issued			150,000
Vicis Capital Master Fund [Member]
Class of Stock [Line Items]
Debt redemption, amount						$ 6,000,000
Officer [Member]
Class of Stock [Line Items]
Additional shares issued				410,348
Warrants exercised, number of shares				500,000
Director [Member]
Class of Stock [Line Items]
Common stock, shares issued						12,500
Additional shares issued						7,065			12,500
Common stock value, Issued						$ 23,166
Shares granted						19,565
Debt redemption, amount					$ 6,000,000

Preferred Stock (Details) - USD ($)		1 Months Ended						8 Months Ended		12 Months Ended
Preferred Stock (Details) - USD ($)	May 12, 2010	Sep. 30, 2011	Sep. 21, 2011	Mar. 25, 2011	Dec. 31, 2010	Nov. 16, 2010	Dec. 31, 2008	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Stock issued, Values										$ 8,795,032
Common Stock [Member]
Class of Stock [Line Items]
Stock issued, Shares										8,333,333
Stock issued, Values										$ 8,333
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Stock issued, Shares	236,598		156,306	176,768		173,922	35
Stock issued, Values							$ 3,500,000	$ 350,000	$ 350,000
Issuance costs							515,000
Net proceeds of shares							$ 2,985,000
Preferred Shares issued, shares							3,500,000
Percentage of cumulative dividend							10.00%			10.00%
Warrants issued										6,000,000
Exercise price							$ 2			$ 2
Treasury stock										100,000
Conversion price										$ 1
Undeclared dividends			$ 350,000
Total Undeclared dividends								$ 350,000	$ 350,000		$ 700,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Stock issued, Shares		15			15
Stock issued, Values					$ 1,500,000					$ 1,500,000
Issuance costs										350,000
Net proceeds of shares										$ 1,150,000
Preferred Shares issued, shares		1,000,000			1,000,000
Percentage of cumulative dividend		10.00%			10.00%					10.00%
Warrants issued		1,000,000			3,000,000
Exercise price		$ 3			$ 3					$ 2
Treasury stock										100,000
Conversion price										$ 1.50
Series B Preferred Stock [Member] \| Common Stock [Member]
Class of Stock [Line Items]
Stock issued, Shares			66,988	75,758
Stock issued, Values		$ 644,540									$ 300,000
Issuance costs										$ 350,000
Preferred shares issued, values										$ 1,158,900
Warrants issued										3,000,000
Warrants, value		$ 855,460								$ 341,100

Warrants (Details 1) - Warrant [Member] - $ / shares	12 Months Ended
Warrants (Details 1) - Warrant [Member] - $ / shares	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Begining balance	11,750,000	12,277,000
Granted	804,139	0
Exercised	(550,000)	0
Cancellation	(10,000,000)
Expired	(150,000)	(527,000)
Ending balance	1,854,139	11,750,000
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Weighted Average Outstanding Roll Forward [Abstract]
Begining balance, weighted average	$ 2.27	$ 2.25
Granted, weighted average	1.20	0
Exercise, weighted average	0.35	0
Expired, weighted average	(2.40)	(1.73)
Cancellation, weighted average	(1.45)
Ending balance, weighted average	$ 1.69	$ 2.27

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2014
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 8 – RELATED PARTY TRANSACTIONS During the year ended December 31, 2010, the Company acquired the technical contributions and assignment of all exclusive rights to and for the SampleMD patent in process at the time from an officer and shareholder in exchange for 300,000 shares of common stock to be granted at the discretion of the seller in addition to 200,000 stock options, which expire in April 2015, that were valued at $360,000. The shares were valued on the grant date at $570,000 and have been recorded as a payable to the related party.

Nature of Business and Basis of Presentation (Details)	Apr. 14, 2008 shares
Nature of Business Details (Textual)
Shares issued by RFID, Ltd. pursuant to a share exchange agreement	1,256,958
Percentage of stock of owned by RFID	100.00%

Commitments and Contingencies (Details) - USD ($)	12 Months Ended
Commitments and Contingencies (Details) - USD ($)	Dec. 31, 2014	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2014
Loss Contingencies [Line Items]
Claims pertaining to damages to nonregistration of shares				$ 450,000
Damage related to LDM' s breach of the agreement.		$ 1,000,000
Loss pertaining to Mr. Milton Wilpon for Litigation settlement	$ 929,000
Contingent Liabilities related to audit fees in percentage	10.00%
Subsequent Event [Member]
Loss Contingencies [Line Items]
Damage related to PDR's actions			$ 900,000

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Summary of Significant Accounting Policies Details (Textual)
Bad debt expense	$ 0	$ 0
Allowance for doubtful accounts	$ 0	$ 0
Revenue recognition and revenue shares, Description	Legal settlement in an amount equal to the greater of 10% of eCoupon revenues generated or $0.37 per eCoupon distributed.
Maximum [Member]
Summary of Significant Accounting Policies Details (Textual)
Property and Equipment, Estimated useful lives	7 years
Minimum [Member]
Summary of Significant Accounting Policies Details (Textual)
Property and Equipment, Estimated useful lives	3 years

Prepaid Expenses (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Prepaid Expenses [Abstract]
Insurance		$ 18,093	$ 6,722
Rent		0	5,049
Legal		10,000	0
Total prepaid expenses	$ 76,376	$ 28,093	$ 11,771

Share Based Payments Options (Details) - USD ($)	3 Months Ended	6 Months Ended		9 Months Ended		12 Months Ended
Share Based Payments Options (Details) - USD ($)	Mar. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013
Share based payments options [Textual]
Stock-based compensation expense	$ 380,217	$ 110,039	$ 170,611	$ (1,066,672)	$ 404,794	$ 899,438	$ 435,612

Property and Equipment (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal		$ 30,607	$ 33,448
Accumulated depreciation		(17,794)	(18,391)
Property and equipment, net	$ 10,674	12,813	15,057
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal		19,519	22,360
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal		$ 11,088	$ 11,088

Property and Equipment (Details Textual) - USD ($)	12 Months Ended
Property and Equipment (Details Textual) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Property and Equipment (Textual)
Depreciation expense	$ 5,933	$ 5,628

Web Based Technology (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Web-based technology, Subtotal		$ 1,197,127	$ 904,710
Accumulated amortization		(633,401)	(440,641)
Impairment		(59,083)	(59,083)
Web-based technology,, net	$ 424,075	504,643	404,986
OptimizeRx web-based technology [Member]
Finite-Lived Intangible Assets [Line Items]
Web-based technology, Subtotal		154,133	154,133
SampleMD web-based technology [Member]
Finite-Lived Intangible Assets [Line Items]
Web-based technology, Subtotal		602,517	602,517
SampleMD 2.0 web-based technology [Member]
Finite-Lived Intangible Assets [Line Items]
Web-based technology, Subtotal		$ 440,477	$ 148,060

Web Based Technology (Details Textuals) - USD ($)	12 Months Ended
Web Based Technology (Details Textuals) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Web-Based Technology [Abstract]
Web-based technology amortization period, Description	Over a period of up to five years.
Web-based technology, amortization expense	$ 192,760	$ 130,289

Patent and Trademarks (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Patent and Trademarks [Abstract]
Patent rights and intangible assets		$ 930,000	$ 930,000
Patent defense costs		170,937	87,993
New patents and trademarks		90,202	62,595
Accumulated amortization		(260,285)	(194,638)
Patent rights and intangible assets, net	$ 901,491	$ 930,854	$ 885,950

Patent and Trademarks (Details Textuals) - USD ($)	1 Months Ended	12 Months Ended
Patent and Trademarks (Details Textuals) - USD ($)	Apr. 26, 2010	Dec. 31, 2014	Jun. 30, 2015	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Accounts payable - related party		$ 570,000	$ 570,000	$ 570,000
Amortizing patent		Straight-line method.
Useful life		17 years
Amortization expense		$ 65,647		$ 57,874
SampleMD Patent Member]
Finite-Lived Intangible Assets [Line Items]
Issuance of common stock: for cash shares	300,000
Stock options	200,000
Shares values	$ 360,000
Expire date	Apr. 30, 2015

Deferred Revenue (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013
Revenue Recognition [Abstract]
Deferred revenue	$ 336,213	$ 120,130	$ 118,949	$ 301,178	$ 437,521	$ 226,272	$ 161,132

Related Party Transactions (Details) - USD ($)	1 Months Ended
Related Party Transactions (Details) - USD ($)	Apr. 26, 2010	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Accounts Payable, Related Parties, Current		$ 570,000	$ 570,000	$ 570,000
Patents [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues	300,000
Stock options	200,000
Expire date	Apr. 30, 2015
Shares values	$ 360,000

Stock Options and Warrants (Details) - $ / shares	12 Months Ended
Stock Options and Warrants (Details) - $ / shares	Dec. 31, 2014	Dec. 31, 2013
Number of shares
Begining balnce , shares	1,180,000	1,484,100
Granted	387,500	2,175,000
Exercised	0
Expired	(260,000)	(2,479,100)
Ending balance, shares	1,307,500	1,180,000
Weighted average exercise price
Begining balance, weighted average exercise price	$ 0.97	$ 0.98
Granted, weighted average exercise price	1.73	1
Exercised, weighted average exercise price	0	0
Expired, weighted average exercise price	(0.39)	(1.00)
Ending balance, weighted average exercise price	$ 1.31	$ 0.97

Stock Options and Warrants (Detail Textuals) - USD ($)	12 Months Ended
Stock Options and Warrants (Detail Textuals) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	387,500	2,175,000
Available for grant, shares	1,307,500	1,180,000	1,484,100
2013 Equity Compensation Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares initially reserved for issuance	1,500,000
Options granted	552,500
Shares granted	537,500
Available for grant, shares	410,000
Compensation cost	$ 272,804	$ 94,998

Warrants (Details)	12 Months Ended
Warrants (Details)	Dec. 31, 2014 $ / shares shares
Warrant one [Member]
Number of Warrants \| shares	1,000,000
Exercise price \| $ / shares	$ 2.25
Expiration Date	May 10, 2017
Warrant two [Member]
Number of Warrants \| shares	50,000
Exercise price \| $ / shares	$ 0.89
Expiration Date	Feb. 17, 2016
Warrant three [Member]
Number of Warrants \| shares	50,000
Exercise price \| $ / shares	$ 1.20
Expiration Date	Mar. 17, 2017

Operating Leases (Details)	Dec. 31, 2014 USD ($)
Operating Leases [Abstract]
Year ended December 31, 2015	$ 62,418
Year ended December 31, 2016	57,217
Total lease commitment	$ 119,635

Major Customers (Details) - USD ($)	3 Months Ended					6 Months Ended		9 Months Ended		12 Months Ended
Major Customers (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Jun. 30, 2015	Jun. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013
Product Information [Line Items]
Total	$ 1,705,457	$ 1,819,421	$ 1,426,808	$ 1,289,428	$ 1,225,169	$ 3,193,010	$ 2,716,236	$ 4,535,857	$ 2,998,546	$ 6,502,962	$ 4,679,741
Revenues Percentage										100.00%	100.00%
Company A [Member]
Product Information [Line Items]
Total										$ 1,270,064	$ 1,776,824
Revenues Percentage										20.00%	36.00%
Company B [Member]
Product Information [Line Items]
Total										$ 797,972	$ 1,053,321
Revenues Percentage										12.00%	22.00%
Company C [Member]
Product Information [Line Items]
Total										$ 772,320	$ 305,980
Revenues Percentage										12.00%	7.00%
Company D [Member]
Product Information [Line Items]
Total										$ 644,702	$ 278,499
Revenues Percentage										10.00%	6.00%
Company E [Member]
Product Information [Line Items]
Total										$ 628,741	$ 71,030
Revenues Percentage										10.00%	2.00%
All other customers [Member]
Product Information [Line Items]
Total										$ 2,389,163	$ 1,193,587
Revenues Percentage										36.00%	25.00%

Major Customers (Detail Textuals)	12 Months Ended
Major Customers (Detail Textuals)	Dec. 31, 2014
Major Customer [Abstract]
Total revenue percentage	10.00%

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Federal income tax benefit attributable to:
Current operations	$ 349,000	$ 91,000
Permanent and Timing Differences (net)	(160,000)	(294,000)
Valuation allowance	(189,000)	203,000
Net provision for federal income tax	$ 0	$ 0

Income Taxes (Details 1) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax asset attributable to:
Net operating loss carryover	$ 2,982,000	$ 2,793,000
Valuation allowance	(2,982,000)	(2,793,000)
Net deferred tax asset	$ 0	$ 0

Income Taxes (Detail Textuals) $ in Millions	12 Months Ended
Income Taxes (Detail Textuals) $ in Millions	Dec. 31, 2014 USD ($)
Income Taxes [Abstract]
Operating loss carryforwards	$ 8.8
Operating loss expire description	Expire from 2027 through 2034 that are available to offset future taxable income.
Effective rate of tax expected	34.00%

Subsequent Events (Details) - Subsequent Event [Member] - shares	1 Months Ended
	Mar. 31, 2015	Jan. 31, 2015
Subsequent Event [Line Items]
Stock issued for advisory services	90,000
Increment One [Member]
Subsequent Event [Line Items]
Stock issued for advisory services	45,000
Outside director [Member]
Subsequent Event [Line Items]
Common stock Issued shares as director fees		12,500